日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer.

利用表面标志物鉴定技术捕获转移性三阴性乳腺癌中的活循环肿瘤细胞。

Lege Bree M, Patel Khushali J, Panici Brendan, Gong Ping, Lewis Michael T, Ellis Matthew J, Cheng Chonghui

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial

更正:氟维司群与阿那曲唑治疗未接受过内分泌治疗的激素受体阳性晚期乳腺癌女性:III期FALCON试验的最终总生存期

Robertson, John F R; Shao, Zhimin; Noguchi, Shinzaburo; Bondarenko, Igor; Panasci, Lawrence; Singh, Sandeep; Subramaniam, Shankar; Ellis, Matthew J

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial

在未接受内分泌治疗的激素受体阳性晚期乳腺癌女性患者中,氟维司群与阿那曲唑的疗效比较:III期FALCON试验的最终总生存期

Robertson, John F R; Shao, Zhimin; Noguchi, Shinzaburo; Bondarenko, Igor; Panasci, Lawrence; Singh, Sandeep; Subramaniam, Shankar; Ellis, Matthew J

NF1-depleted ER(+) breast cancers are differentially sensitive to CDK4/6 inhibitors

NF1 缺失的 ER(+) 乳腺癌对 CDK4/6 抑制剂的敏感性存在差异

Zheng, Ze-Yi; Chen, Anran; Jaehnig, Eric J; Anurag, Meenakshi; Lei, Jonathan T; Feng, Long; Wang, Chenwei; Fandino, Diana; Singh, Purba; Kennedy, Hilda; Yadav, Ghazal; Vollert, Craig T; Tsai, Jill; Chen, Xi; Li, Yi; Lim, Bora; Thompson, Alastair; Li, Shunqiang; Foulds, Charles E; Zhang, Bing; Ellis, Matthew J; Chang, Eric C

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.

CALGB 40601(Alliance)HER2+乳腺癌新辅助治疗试验的蛋白质基因组学分析揭示了耐药生物标志物

Jaehnig Eric J, Fernandez-Martinez Aranzazu, Vashist Tanmayi D, Holt Matthew V, Williams LaTerrica, Lei Jonathan T, Moon Chang In, Kim Beom-Jun, Dou Yongchao, Zhao Haoquan, Korchina Viktoriya, Gibbs Richard A, Muzny Donna Marie, Doddapaneni Harshavardhan, Perou Charles M, Carey Lisa A, Robles Ana I, Hyslop Terry, Wen Yujia, McCart Linda, Krek Azra, Petralia Francesca, Miles George, Kavuri Shyam M, Gillette Michael A, Mani D R, Carr Steven A, Zhang Bing, Ellis Matthew J, Satpathy Shankha, Anurag Meenakshi

Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer

更正:RON信号通路促进ESR1突变型乳腺癌的治疗耐药性

Dustin, Derek; Gu, Guowei; Beyer, Amanda R; Herzog, Sarah K; Edwards, David G; Lin, Hangqing; Gonzalez, Thomas L; Grimm, Sandra L; Coarfa, Cristian; Chan, Doug W; Kim, Beom-Jun; De La O, Jean-Paul; Ellis, Matthew J; Liu, Dan; Li, Shunqiang; Welm, Alana L; Fuqua, Suzanne A W

Improving deceased donor kidney utilization: predicting risk of nonuse with interpretable models

提高已故捐献肾脏的利用率:利用可解释模型预测肾脏未被使用的风险

Li, Ruoting; Tunç, Sait; Özaltın, Osman Y; Ellis, Matthew J

System Interventions to Achieve Early and Equitable Kidney Transplants (STEPS): Protocol for STEPS, a randomized comparative effectiveness clinical trial

系统干预以实现早期和公平的肾移植(STEPS):STEPS方案,一项随机对照疗效临床试验

Boulware, L Ebony; Ephraim, Patti L; Shafi, Tariq; Green, Jamie A; Browne, Teri; Strigo, Tara S; Peskoe, Sarah; Wilson, Jonathan; Lokhnygina, Yuliya; Alkon, Aviel; Jackson, George L; Ellis, Matthew J; Sudan, Debra; Cameron, Blake; Vaitla, Pradeep K; Cabacungan, Ashley; Brubaker, Lauren; Obermiller, Emily L; Diamantidis, Clarissa J

Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.

源自患者的三阴性乳腺癌异种移植模型能够对化疗反应进行解卷积和预测

Lei Jonathan T, Dobrolecki Lacey E, Huang Chen, Srinivasan Ramakrishnan R, Vasaikar Suhas V, Lewis Alaina N, Sallas Christina, Zhao Na, Cao Jin, Landua John D, Moon Chang In, Liao Yuxing, Hilsenbeck Susan G, Osborne C Kent, Rimawi Mothaffar F, Ellis Matthew J, Petrosyan Varduhi, Wen Bo, Li Kai, Saltzman Alexander B, Jain Antrix, Malovannaya Anna, Wulf Gerburg M, Marangoni Elisabetta, Li Shunqiang, Kraushaar Daniel C, Wang Tao, Damodaran Senthil, Zheng Xiaofeng, Meric-Bernstam Funda, Echeverria Gloria V, Anurag Meenakshi, Chen Xi, Welm Bryan E, Welm Alana L, Zhang Bing, Lewis Michael T

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial

接受新辅助阿那曲唑、氟维司群或二者联合治疗的雌激素受体丰富/ERBB2阴性绝经后乳腺癌患者的内分泌敏感性疾病发生率:一项3期随机临床试验

Ma, Cynthia X; Suman, Vera J; Sanati, Souzan; Vij, Kiran; Anurag, Meenakshi; Leitch, A Marilyn; Unzeitig, Gary W; Hoog, Jeremy; Fernandez-Martinez, Aranzazu; Fan, Cheng; Gibbs, Richard A; Watson, Mark A; Dockter, Travis J; Hahn, Olwen; Guenther, Joseph M; Caudle, Abigail; Crouch, Erika; Tiersten, Amy; Mita, Monica; Razaq, Wajeeha; Hieken, Tina J; Wang, Yang; Rimawi, Mothaffar F; Weiss, Anna; Winer, Eric P; Hunt, Kelly K; Perou, Charles M; Ellis, Matthew J; Partridge, Ann H; Carey, Lisa A